Pacira BioSciences (PCRX) 주식 개요
는 미국 내 의료 종사자를 대상으로 비오피오이드 통증 관리 및 재생 건강 솔루션을 개발, 제조, 마케팅, 유통, 판매하는 회사입니다. 자세히 보기
PCRX Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pacira BioSciences, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$24.36 |
| 52주 최고가 | US$27.64 |
| 52주 최저가 | US$18.80 |
| 베타 | 0.32 |
| 1개월 변동 | -0.61% |
| 3개월 변동 | 3.84% |
| 1년 변동 | -5.65% |
| 3년 변동 | -37.95% |
| 5년 변동 | -61.09% |
| IPO 이후 변동 | 247.01% |
최근 뉴스 및 업데이트
Recent updates
Seeking Alpha • May 19
Pacira BioSciences: Exparel Still Supports My Original Bull Case
Summary PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That’s why I think the most important catalysts for this stock, for better or worse, will be its upcoming 2026 pipeline readouts. But I reckon that PCRX’s overdependence on Exparel remains a factor worth considering, aside from other inherent biotech risks like patents and reimbursement policies, among others. Fortunately, PCRX’s recent pullback actually offers a discount on a relatively improved company compared to the first time I covered it. As such, I reiterate my “Buy” on PCRX. Read the full article on Seeking Alpha
내러티브 업데이트 • May 01
PCRX: Real World Procedure Data Will Support Future Upside Repricing
Analysts nudged their price target on Pacira BioSciences up by $2, citing slightly stronger modeled revenue growth of 17.50% and an 8.33% profit margin outlook, supported by recent real world data updates and mixed but active coverage on the stock. Analyst Commentary Recent research has been mixed, but the latest commentary highlights that bullish analysts are still finding reasons to lean constructive on Pacira BioSciences, especially around the updated revenue growth and margin framework that underpins the new price target.
내러티브 업데이트 • Apr 16
PCRX: Real World Hip Data And Activist Pressure Will Shape Outlook
Analysts have reduced their Pacira BioSciences price target by $2, citing updated real world data in hip arthroplasty and revisions to growth, margin, and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that updated real world hip arthroplasty data has introduced more uncertainty into Pacira BioSciences' outlook, leading to more cautious assumptions around growth, margin profile, and future P/E levels.내러티브 업데이트 • Apr 01
PCRX: Higher 2026 Outlook And Activist Pressure Will Unlock Future Upside
Analysts have trimmed their Pacira BioSciences price target by $2, citing updated assumptions around faster revenue growth, a lower profit margin outlook, and a higher future P/E multiple. Analyst Commentary Despite the modest trim to the headline price target, bullish analysts see the updated assumptions as a way to reset expectations while keeping a constructive view on Pacira BioSciences.내러티브 업데이트 • Mar 17
PCRX: Future Outlook Weighs Activist Board Push Against Asia Licensing Upside
Analysts have reaffirmed their $22.00 price target for Pacira BioSciences, noting small adjustments to revenue growth, profit margin assumptions, and a slightly lower future P/E multiple to reflect updated expectations for the company’s earnings profile. What's in the News DOMA Perpetual Capital Management nominated three director candidates for the 2026 annual meeting and called for the immediate replacement of CEO Frank Lee, the appointment of an interim CEO, and a formal sale process for the business (Investor activism, March 12, 2026).내러티브 업데이트 • Mar 03
PCRX: Future Outlook Balances Asia Partnership Progress With Activist Pressure
Analysts have trimmed their price target on Pacira BioSciences from $24 to $22, reflecting updated assumptions that include a higher discount rate, more conservative revenue expectations, and lower projected profit margins, partly offset by a slightly higher future P/E multiple. What's in the News Issued full year 2026 earnings guidance, with total revenue expected in a range of $745 million to $770 million.내러티브 업데이트 • Feb 17
PCRX: Asia Partnership Will Drive Future Upside Potential
Analysts have kept their $38.00 price target for Pacira BioSciences steady, with only small tweaks to assumptions around revenue growth, profit margins and future P/E that support this unchanged view. What's in the News Pacira BioSciences entered an agreement with LG Chem that gives LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.내러티브 업데이트 • Feb 02
PCRX: Asia Partnerships And Pipeline Progress Will Drive Future Upside Potential
Analysts have reiterated a US$38.00 price target for Pacira BioSciences, citing slightly updated assumptions for revenue growth, profit margin, and future P/E that collectively leave their overall valuation view unchanged. What's in the News Pacira entered an agreement with LG Chem, giving LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets, with Pacira receiving an upfront payment, transfer price, and tiered royalties while LG Chem handles regulatory filings in South Korea and Thailand within six months (Client Announcements).내러티브 업데이트 • Jan 19
PCRX: Asia Partnership And Pipeline Advances Will Drive Future Upside Potential
Narrative Update Analysts have kept their price target for Pacira BioSciences broadly steady around $38.00, citing slightly higher modeled revenue growth, a modestly lower profit margin outlook, and a similar forward P/E assumption. What’s in the News Pacira entered an agreement with LG Chem, granting LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.분석 기사 • Jan 17
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive
Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders won't be pleased to see that the share price has had a very rough...내러티브 업데이트 • Jan 05
PCRX: Share Buybacks And Activist Pressure Will Support Future Upside Potential
Analysts have kept their fair value estimate for Pacira BioSciences steady at $38.00. The latest price target is grounded in updated assumptions for slightly different revenue growth, profit margin expectations, and a higher future P/E multiple.내러티브 업데이트 • Dec 14
PCRX: Activist Pressure And Share Buybacks Will Unlock Future Upside Potential
Analysts have modestly raised their price target on Pacira BioSciences to $38.00 from $36.00, citing expectations for slightly stronger long term profitability despite a somewhat more conservative revenue growth outlook and valuation multiple. What's in the News Activist investor DOMA Perpetual Capital Management sent a letter to Pacira's board urging the company to hire bankers and pursue a full sale process, citing persistent underperformance and overspending (Key Developments).분석 기사 • Nov 13
Pacira BioSciences' (NASDAQ:PCRX) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Pacira BioSciences, Inc.'s...
내러티브 업데이트 • Aug 17
Policy Changes And Partnerships Will Expand Ambulatory Market Reach
The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00. What's in the News Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.분석 기사 • Jun 11
Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Apr 09
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
Summary PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which creates separate reimbursement and grows access to non-opioid therapies. Also, PCRX’s PCRX-201 is a promising new gene therapy for knee osteoarthritis, which so far has shown promising results and targets a sizeable TAM. I also like how PCRX reached important patent settlements that secure its competitive prospects with Exparel’s exclusivity until 2030. In my view, PCRX remains undervalued at these levels, which is why I consider it a “Buy” despite its inherent biotech risks. Read the full article on Seeking Alpha분석 기사 • Apr 07
Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...Seeking Alpha • Mar 14
Pacira BioSciences: Back On An Uptrend After Positive Developments
Summary Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act. Pacira's new five-point plan aims for growth, profitability, and pipeline expansion, positioning it for potential blockbuster revenue and market leadership. The positive steps PCRX has taken since my last note means there is no change to my “buy” thesis. Read the full article on Seeking Alpha분석 기사 • Jan 30
Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jan 03
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
You may think that with a price-to-sales (or "P/S") ratio of 1.2x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...Seeking Alpha • Nov 25
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Summary Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's share price has plummeted from >$80 in mid-2022 to ~$18 today, as the market sees little growth in the business and notes the competitive threats. The market may be a little too pessimistic - Vertex's drug is unproven in the market while generics may be held off for many more years. EXPAREL's peak years may still be ahead - PCRX stock could recoup some deserved value if it can share positive Q4 earnings, update on legal matters, and keep developing its pipeline. Read the full article on Seeking Alpha
새로운 내러티브 • Sep 24
EXPAREL's Calculated Expansion And Innovative R&D Bolster Market Dominance Amidst Challenges
Expanding EXPAREL utilization in outpatient settings and through GPO partnerships aims to enhance revenue by increasing market penetration and affordability.분석 기사 • Sep 06
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
To the annoyance of some shareholders, Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shares are down a considerable 34% in...분석 기사 • Jul 23
Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders that were waiting for something to happen have been dealt a blow...주주 수익률
| PCRX | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | 9.2% | 2.6% | 2.5% |
| 1Y | -5.7% | 41.5% | 26.4% |
수익률 대 산업: PCRX은 지난 1년 동안 41.5%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: PCRX은 지난 1년 동안 26.4%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| PCRX volatility | |
|---|---|
| PCRX Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: PCRX는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: PCRX의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2006 | 827 | Frank Lee | www.pacira.com |
는 비오피오이드 통증 관리 및 재생 건강 솔루션을 개발, 제조, 마케팅, 유통, 판매하여 미국 내 의료진에게 제공하는 회사입니다. 이 회사는 수술 후 통증 관리를 위한 부피바카인 리포솜 주사용 현탁액인 엑스파렐, 골관절염 및 무릎 통증 관리에 사용되는 트리암시놀론 아세토나이드 서방형 주사용 현탁액인 질레타, 말초 신경의 통증 전달 신호를 차단하는 신경 용해 차단을 생성하기 위해 표적 신경에 제어 용량의 냉온을 전달하는 비오피오이드 휴대용 냉동 진통제 장치인 아이오베라 시스템을 공급하고 있습니다. 또한 골관절염과 같이 유병률이 높은 질환을 치료할 수 있는 유전자 의약품을 국소 투여할 수 있는 새로운 유전자 치료 벡터 플랫폼인 PCRX-201을 개발하고 있습니다.
Pacira BioSciences, Inc. 기초 지표 요약
| PCRX 기초 통계 | |
|---|---|
| 시가총액 | US$918.77m |
| 순이익 (TTM) | US$5.14m |
| 매출 (TTM) | US$734.86m |
186.6x
주가수익비율(P/E)1.3x
주가매출비율(P/S)PCRX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| PCRX 손익계산서 (TTM) | |
|---|---|
| 매출 | US$734.86m |
| 매출원가 | US$151.86m |
| 총이익 | US$583.01m |
| 기타 비용 | US$577.87m |
| 순이익 | US$5.14m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 0.13 |
| 총이익률 | 79.34% |
| 순이익률 | 0.70% |
| 부채/자본 비율 | 56.2% |
PCRX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 16:45 |
| 종가 | 2026/05/26 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Pacira BioSciences, Inc.는 29명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jenna Davidner | Barclays |
| Anita Dushyanth | Berenberg |
| Gary Nachman | BMO Capital Markets Equity Research |